用RNA和化疗的组合准内瘤
Abdulhamid S Fatani1, Andreas G Schätzlein1,2, Ijeoma F Uchegbu1,2
1UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK.
Pharmaceutics
|June 27, 2024
概括
这项研究表明,将ITCH siRNA与通过鼻到大脑输送的gemcitabine结合起来,在脑瘤模型中显著改善了生存率. 这种方法可以提高化学疗法的有效性,以对多种质母细胞瘤进行攻击性治疗.
科学领域:
- 在瘤学瘤学.
- 纳米技术纳米技术
- 分子生物学分子生物学
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有不良预后和有限治疗选择的侵袭性脑瘤.
- 在癌症中过度表达的E3酶ITCH抑制了瘤抑制剂p73.
- 针对ITCH提供了一种潜在的策略,以提高GBM治疗疗效.
研究的目的:
- 为了研究ITCH siRNA和gemcitabine在GBM治疗中的协同作用.
- 在内GBM模型中评估GC60-siRNA-ITCH和gemcitabine鼻到脑输送的疗效.
- 评估组合治疗对瘤生长,亡和动物生存的影响.
主要方法:
- 使用U87-MG细胞进行体外研究,以评估协同效应,ITCH下调,p73上调和通过qPCR,西斑,显微镜,流细胞计和细胞毒性测定来评估apoptosis.
- 在体内研究CD-1裸体小鼠与内U87-MG-luc2瘤.
- 鼻子到大脑输送6O-glycolchitosan (GC) 封装的siRNA ITCH (GC60-siRNA-ITCH) 和gemcitabine.
主要成果:
- 实验室研究证实了siRNA-ITCH和凝胺的协同作用,导致ITCH下调,p73上调和增强的亡.
- 结合疗法在体外减少了细胞增殖.
- 在体内,鼻腔内注射凝胺显著增加了生存时间 (29至45天).
- 结合疗法 (GC60-siRNA-ITCH + gemcitabine) 与未经治疗的对照组相比,使得生存时间 (29至54天) 增加了89% (p < 0.01).
结论:
- 针对ITCH的siRNA可以使大脑瘤对gemcitabine产生化学敏感性.
- 鼻至脑输送是治疗内瘤的可行策略.
- 组合疗法对改善多种质母细胞瘤的结果具有显著的前景.
关键词:
6-O-glycolchitosan 的使用情况.大脑大脑大脑的大脑大脑大脑传递 大脑传递基因治疗的基因疗法内瘤是一种内瘤.这是一种鼻腔内科的治疗方法.siRNA 抗 ITCH 的抗 ITCH 的更多相关视频
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
3.0K
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
252
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
510
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510
